Altimmune (ALT) Accounts Payables (2010 - 2026)

Altimmune (ALT) has 17 years of Accounts Payables data on file, last reported at $1.5 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $1.5 million, up 42.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 million (up 42.06% YoY), and the FY2025 annual result was $2.7 million, up 1187.68% from the prior year.
• Accounts Payables retreated to $1.5 million in Q1 2026 per ALT's latest filing, from $2.7 million in the prior quarter.
• Over five years, Accounts Payables peaked at $5.2 million in Q1 2023 and troughed at $211000.0 in Q4 2024.
• A 5-year average of $2.6 million and a median of $2.7 million in 2024 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2022 and 2024: Accounts Payables soared 23227.31% in 2022, then slumped 89.81% in 2024.
• A 5-year view of Accounts Payables shows it stood at $4.8 million in 2022, then slumped by 56.91% to $2.1 million in 2023, then tumbled by 89.81% to $211000.0 in 2024, then jumped by 1187.68% to $2.7 million in 2025, then tumbled by 43.69% to $1.5 million in 2026.
• Business Quant data shows ALT's Accounts Payables at $1.5 million in Q1 2026, $2.7 million in Q4 2025, and $4.8 million in Q3 2025.